Management of Chronic Migraines in Patients with Viral Meningitis

Introduction to Management

The American College of Physicians recommends managing chronic migraines as a separate condition requiring migraine-specific preventive therapy, while viral meningitis receives supportive care with analgesics for acute headache relief 1, 2

Supportive care is the mainstay for viral meningitis, as no specific antiviral treatment is recommended for most cases, according to the Infectious Diseases Society of America 3, 4, 1
The American Academy of Neurology recommends acetaminophen and NSAIDs (ibuprofen, naproxen) for headache relief in viral meningitis, though caution is warranted as NSAIDs can rarely cause aseptic meningitis 1, 5

The American Headache Society recommends starting with one of these evidence-based first-line agents for migraine preventive therapy: propranolol 80-240 mg/day, timolol 20-30 mg/day, topiramate 100 mg/day, or candesartan, particularly if the patient has comorbid hypertension 2
The American Academy of Neurology suggests an implementation strategy of starting at a low dose and titrating slowly over 2-3 weeks until clinical benefits are achieved or side effects limit further increases, with an adequate trial period of 2-3 months required before determining efficacy 2

The Infectious Diseases Society of America recommends supporting a staged return to work or studies, starting part-time initially, and considering early referral to mental health services if emotional difficulties develop 6, 1
Post-discharge follow-up should be offered to all patients with confirmed viral meningitis, as many issues only become apparent after discharge, according to the Journal of Infection 6

Failing to distinguish between viral meningitis headache and chronic migraine, which require different management approaches, is a common pitfall to avoid, as stated by the American College of Physicians 1, 5
Starting preventive medications at too high a dose, leading to poor tolerability and discontinuation, should be avoided, according to the American Headache Society 2
Inadequate duration of preventive trial, less than 2-3 months before declaring treatment failure, is another pitfall to avoid, as recommended by the American Academy of Neurology 2
Missing medication overuse headache from frequent use of acute medications, which undermines preventive therapy, should be avoided, according to the American Headache Society 2